Research and
education
deserve attention.

Which is just
what we create.

 
Latest news from Facebook Facebook

PR&D - Public Relations für Forschung & Bildung added an event. ... See MoreSee Less

Eintritt frei! Getränke & Networking ab ca. 19:30 Uhr Vortragende Prof. Thomas Niederkrotenthaler Medizinische Universität Wien, Institut für Sozialmedizin Saskia Jungnikl Autorin Mittwoch 28. ...

AM PULS Nr. 51 Suizid - Tabuthema mitten in der Gesellschaft

September 28, 2016, 6:00pm - September 28, 2016, 9:00pm

Theater Akzent

Eintritt frei! Getränke & Networking ab ca. 19:30 Uhr Vortragende Prof. Thomas Niederkrotenthaler Medizinische Universität Wien, Institut für Sozialmedizin Saskia Jungnikl Autorin Mittwoch 28. ...

16.08.16

PR&D - Public Relations für Forschung & Bildung added a new photo — feeling fantastic at Theater Akzent. ... See MoreSee Less

06.06.16

View on Facebook
Upcoming Events

AM PULS Nr. 51

Suicide

Taboo Issue at the Center of Society

(in German only)

ampuls_neu4.indd

 

Wednesday, 28 September 2016, 6 pm

More Info

 

Kunden-News

7. September 2016

Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson’s Disease Vaccine against Alpha-Synuclein:

PD01A was Safe and Well Tolerated: Primary Endpoint of Phase I “Boost” Study Met Immune Response was Seen in 86% of Patients, Resulting in an Increase of Responder Rate after Boost Immunization PD01A-induced Antibodies Preferentially Bind to Fibrilic Alpha-Synuclein (aSyn) Data will be Presented at the Poster Tour of Leading Abstracts at the 4th World […]

News lesen

Kunden-News

25. August 2016

Themis Bioscience: Phase 2 Trial of leading Chikungunya Vaccine candidate started:

Vienna, 25 August 2016 – With the first patient vaccinated, a Phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally and is developed by the Austrian biotech company Themis Bioscience GmbH. It is based on the company’s proprietary Themaxyn® […]

News lesen